Literature DB >> 8335355

Group B streptococcal neuraminidase is actually a hyaluronidase.

D G Pritchard1, B Lin.   

Abstract

The extracellular group B streptococcal enzyme described in numerous reports as a neuraminidase is really a hyaluronidase. Over the past 25 years, the enzyme was routinely assayed with bovine submaxillary mucin as the substrate and by the thiobarbituric acid procedure to measure released sialic acid. Characterization of the actual compound released by the enzyme revealed it to be an alpha,beta-unsaturated derivative of hyalobiuronic acid that was derived from hyaluronic acid contaminating the mucin preparation. Previous reports describing an association of elevated levels of extracellular neuraminidase with virulent strains of group B streptococci must be reevaluated with the recognition that the enzyme is really a hyaluronidase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8335355      PMCID: PMC280993          DOI: 10.1128/iai.61.8.3234-3239.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Cytotoxic contaminants in commercial Clostridium perfringens neuraminidase preparations purified by affinity chromatography.

Authors:  H Den; D A Malinzak; A Rosenberg
Journal:  J Chromatogr       Date:  1975-08-20

2.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

3.  Association of elevated levels of extracellular neuraminidase with clinical isolates of type III group B streptococci.

Authors:  T W Milligan; C J Baker; D C Straus; S J Mattingly
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

4.  Treatment of bovine nasal cartilage proteoglycan with chondroitinases from Flavobacterium heparinum and Proteus vulgaris.

Authors:  V C Hascall; R L Riolo; J Hayward; C C Reynolds
Journal:  J Biol Chem       Date:  1972-07-25       Impact factor: 5.157

5.  Purification and characterization of bovine and ovine submaxillary mucins.

Authors:  G Tettamanti; W Pigman
Journal:  Arch Biochem Biophys       Date:  1968-03-20       Impact factor: 4.013

6.  Sialidase-like enzymes produced by group A, B, C, G, and L streptococci and by Streptococcus sanguis.

Authors:  S Hayano; A Tanaka
Journal:  J Bacteriol       Date:  1969-03       Impact factor: 3.490

7.  Growth characteristics of group A streptococci in a new chemically defined medium.

Authors:  I van de Rijn; R E Kessler
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

8.  A procedure for the rapid, quantitative N-acetylation of amino sugar methyl glycosides.

Authors:  J R Etchison; J J Holland
Journal:  Anal Biochem       Date:  1975-05-26       Impact factor: 3.365

9.  Stable thiobarbituric acid chromophore with dimethyl sulphoxide. Application to sialic acid assay in analytical de-O-acetylation.

Authors:  L Skoza; S Mohos
Journal:  Biochem J       Date:  1976-12-01       Impact factor: 3.857

10.  Serotypes of group B streptococci and their relation to hyaluronidase production and hydrolysis of salicin.

Authors:  E Kjems; B Perch; J Henrichsen
Journal:  J Clin Microbiol       Date:  1980-02       Impact factor: 5.948

View more
  8 in total

Review 1.  Mucinases and sialidases: their role in the pathogenesis of sexually transmitted infections in the female genital tract.

Authors:  R Wiggins; S J Hicks; P W Soothill; M R Millar; A P Corfield
Journal:  Sex Transm Infect       Date:  2001-12       Impact factor: 3.519

Review 2.  The Double Life of Group B Streptococcus: Asymptomatic Colonizer and Potent Pathogen.

Authors:  Blair Armistead; Elizabeth Oler; Kristina Adams Waldorf; Lakshmi Rajagopal
Journal:  J Mol Biol       Date:  2019-01-31       Impact factor: 5.469

Review 3.  Pneumococcal virulence factors: structure and function.

Authors:  M J Jedrzejas
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

4.  Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease.

Authors:  M Hauge; C Jespersgaard; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

5.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae.

Authors:  Herve Tettelin; Vega Masignani; Michael J Cieslewicz; Jonathan A Eisen; Scott Peterson; Michael R Wessels; Ian T Paulsen; Karen E Nelson; Immaculada Margarit; Timothy D Read; Lawrence C Madoff; Alex M Wolf; Maureen J Beanan; Lauren M Brinkac; Sean C Daugherty; Robert T DeBoy; A Scott Durkin; James F Kolonay; Ramana Madupu; Matthew R Lewis; Diana Radune; Nadezhda B Fedorova; David Scanlan; Hoda Khouri; Stephanie Mulligan; Heather A Carty; Robin T Cline; Susan E Van Aken; John Gill; Maria Scarselli; Marirosa Mora; Emilia T Iacobini; Cecilia Brettoni; Giuliano Galli; Massimo Mariani; Filippo Vegni; Domenico Maione; Daniela Rinaudo; Rino Rappuoli; John L Telford; Dennis L Kasper; Guido Grandi; Claire M Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-28       Impact factor: 11.205

6.  Molecular characterization of the cfb gene encoding group B streptococcal CAMP-factor.

Authors:  A Podbielski; O Blankenstein; R Lütticken
Journal:  Med Microbiol Immunol       Date:  1994-11       Impact factor: 3.402

7.  Distribution, genetic diversity, and variable expression of the gene encoding hyaluronate lyase within the Streptococcus suis population.

Authors:  Samantha J King; Andrew G Allen; Duncan J Maskell; Christopher G Dowson; Adrian M Whatmore
Journal:  J Bacteriol       Date:  2004-07       Impact factor: 3.490

8.  Cloning and nucleotide sequence of the Streptococcus pneumoniae hyaluronidase gene and purification of the enzyme from recombinant Escherichia coli.

Authors:  A M Berry; R A Lock; S M Thomas; D P Rajan; D Hansman; J C Paton
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.